Search

Your search keyword '"Mukhopadhyay, Pabak"' showing total 21 results
Start Over Author "Mukhopadhyay, Pabak"
21 results on '"Mukhopadhyay, Pabak"'

2. Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy

Author

Poynard, Thierry, Colombo, Massimo, Bruix, Jordi, Schiff, Eugene, Terg, Ruben, Flamm, Steven, Moreno-Otero, Ricardo, Carrilho, Flair, Schmidt, Warren, Berg, Thomas, McGarrity, Thomas, Heathcote, E. Jenny, Gonçales, Fernando, Diago, Moises, Craxi, Antonio, Silva, Marcelo, Bedossa, Pierre, Mukhopadhyay, Pabak, Griffel, Louis, Burroughs, Margaret, Brass, Clifford, and Albrecht, Janice

Published
2009
Full Text
View/download PDF

3. Peginterferon Alfa-2b orAlfa-2a with ribavirin for treatment of hepatitis C infection

Author

McHutchison, John G., Lawitz, Eric J., Shiffman, Mitchell L., Muir, Andrew J., Galler, Greg W., McCone, Jonathan, Nyberg, Lisa M., Lee, William M., Ghalib, Reem H., Schiff, Eugene R., Galati, Joseph S., Bacon, Bruce R., Davis, Mitchell N., Mukhopadhyay, Pabak, Koury, Kenneth, Noviello, Stephanie, Pedicone, Lisa D., Brass, Clifford A., Albrecht, Janice K., and Sulkowski, Mark S.

Subjects
Drug therapy, Combination -- Usage, Hepatitis C -- Drug therapy, Peginterferon alfa-2a -- Comparative analysis, Peginterferon alfa-2a -- Usage, Peginterferon alfa-2b -- Comparative analysis, Peginterferon alfa-2b -- Usage, Ribavirin -- Usage, Ribavirin -- Comparative analysis
Abstract

A study was conducted to evaluate and compare the efficacy of peginterferon Alfa-2b against Alfa-2a with ribavirin for the treatment of patients with hepatitis C infection. Results indicated that there was not much significant difference in treatment with any of these regimens.

Published
2009

5. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

Author

Baselga, José, Campone, Mario, Piccart, Martine, Burris, Howard A., III, Rugo, Hope S., Sahmoud, Tarek, Noguchi, Shinzaburo, Gnant, Michael, Pritchard, Kathleen I., Lebrun, Fabienne, Beck, Thaddeus J., Ito, Yoshinori, Yardley, Denise, Deleu, Ines, Perez, Alejandra, Bachelot, Thomas, Vittori, Luc, Xu, Zhiying, Mukhopadhyay, Pabak, Lebwohl, David, and Hortobagyi, Gabriel N.

Published
2012
Full Text
View/download PDF

6. Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

Author

McHutchison, John G., Lawitz, Eric J., Shiffman, Mitchell L., Muir, Andrew J., Galler, Greg W., McCone, Jonathan, Nyberg, Lisa M., Lee, William M., Ghalib, Reem H., Schiff, Eugene R., Galati, Joseph S., Bacon, Bruce R., Davis, Mitchell N., Mukhopadhyay, Pabak, Koury, Kenneth, Noviello, Stephanie, Pedicone, Lisa D., Brass, Clifford A., Albrecht, Janice K., and Sulkowski, Mark S.

Published
2009
Full Text
View/download PDF

9. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3).

Author

O'Regan, Ruth, primary, Ozguroglu, Mustafa, additional, Andre, Fabrice, additional, Toi, Masakazu, additional, Jerusalem, Guy Heinrich Maria, additional, Wilks, Sharon, additional, Isaacs, Claudine, additional, Xu, Binghe, additional, Masuda, Norikazu, additional, Arena, Francis P., additional, Yardley, Denise Aysel, additional, Yap, Yoon Sim, additional, Mukhopadhyay, Pabak, additional, Douma, Shyanne, additional, El-Hashimy, Mona, additional, Taran, Tanya, additional, Sahmoud, Tarek, additional, Lebwohl, David Edward, additional, and Gianni, Luca, additional

Published
2013
Full Text
View/download PDF

10. Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.

Author

Rugo, Hope S., primary, Burris, Howard A., additional, Gnant, Michael, additional, Baselga, José, additional, Piccart-Gebhart, Martine J., additional, Noguchi, Shinzaburo, additional, Dakhil, Shaker R., additional, Srimuninnimit, Vichien, additional, Puttawibul, Puttisak, additional, Csoszi, Tibor, additional, Heng, Daniel Yick Chin, additional, Bourgeois, Hugues, additional, Gonzalez-Martin, Antonio, additional, Osborne, Karen, additional, Mukhopadhyay, Pabak, additional, Taran, Tanya, additional, Campone, Mario, additional, Hortobagyi, Gabriel N., additional, Sahmoud, Tarek, additional, and Pritchard, Kathleen I., additional

Published
2012
Full Text
View/download PDF

11. BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2+), locally advanced or metastatic breast cancer (BC).

Author

Hurvitz, Sara A., primary, Andre, Fabrice, additional, Burris, Howard A., additional, Toi, Masakazu, additional, Buyse, Marc E., additional, Sahmoud, Tarek, additional, Mukhopadhyay, Pabak, additional, Massacesi, Cristian, additional, Taran, Tanya, additional, Ko, Jennifer, additional, and Rupin, Matthieu, additional

Published
2012
Full Text
View/download PDF

12. Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.

Author

Pritchard, Kathleen I., primary, Burris, Howard A., additional, Rugo, Hope S., additional, Gnant, Michael, additional, Baselga, José, additional, Piccart-Gebhart, Martine J., additional, Noguchi, Shinzaburo, additional, Dakhil, Shaker R., additional, Srimuninnimit, Vichien, additional, Puttawibul, Puttisak, additional, Osborne, Karen, additional, Mukhopadhyay, Pabak, additional, Taran, Tanya, additional, Sahmoud, Tarek, additional, Campone, Mario, additional, and Hortobagyi, Gabriel N., additional

Published
2012
Full Text
View/download PDF

14. 831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3

Author

Poynard, Thierry, primary, Schiff, Eugene R., additional, Terg, Ruben, additional, Moreno-Otero, Ricardo, additional, Flamm, Steven L., additional, Schmidt, Warren N., additional, Berg, Thomas, additional, Goncales, Fernando L., additional, Heathcote, Jenny, additional, Diago, Moises, additional, McGarrity, Thomas, additional, Bedossa, Pierre, additional, Zhou, Honghong, additional, Mukhopadhyay, Pabak, additional, Griffel, Louis H., additional, Burroughs, Margaret, additional, Brass, Clifford A., additional, and Albrecht, Janice, additional

Published
2009
Full Text
View/download PDF

15. S1000 Results from the Epic3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the RE-Treatment of Previous Interferon/Ribavirin Non-Responders (Nr)

Author

Poynard, Thierry, primary, Schiff, Eugene, additional, Terg, Ruben, additional, Moreno-Otero, Ricardo, additional, Flamm, Steven L., additional, Schmidt, Warren N., additional, Berg, Thomas, additional, Goncales, Fernando L., additional, Heathcote, Jenny, additional, Diago, Moises, additional, McGarrity, Thomas J., additional, Bedossa, Pierre, additional, Deng, Weipeng, additional, Mukhopadhyay, Pabak, additional, Griffel, Louis H., additional, Burroughs, Margaret, additional, Brass, Clifford A., additional, and Albrecht, Janice, additional

Published
2008
Full Text
View/download PDF

19. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.

Author

Melani, Lorenzo, Mills, Richard, Hassman, David, Lipetz, Robert, Lipka, Leslie, LeBeaut, Alexandre, Suresh, Ramachandran, Mukhopadhyay, Pabak, and Veltri, Enrico

Abstract

Aims To evaluate the efficacy and safety of ezetimibe 10mg administered with pravastatin in patients with primary hypercholesterolemia.Methods and results After dietary stabilization, 2–12 week screening/washout period, and 4-week, single-blind, placebo lead-in period, 538 patients with baseline LDL-C ≥3.8 to ≤6.5mmol/l and TG ≤4.0mmol/l were randomized to one of eight possible treatments administered daily for 12 weeks: ezetimibe 10mg; pravastatin 10, 20, or 40mg; ezetimibe 10mg plus pravastatin 10, 20, or 40mg; or placebo. The primary efficacy endpoint was percent reduction in LDL-C from baseline to study endpoint for ezetimibe 10mg plus pravastatin (pooled doses) compared to pravastatin alone (pooled doses) and ezetimibe alone. The combined use of ezetimibe and pravastatin resulted in significant incremental reductions in LDL-C and TG compared to pooled pravastatin alone \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \((p{<}0.01)\) \end{document}. Coadministration therapy reduced LDL-C by 34–41%, TG by 21–23%, and increased HDL-C by 7.8–8.4%, depending on the dose of pravastatin. The combined regimen was well tolerated, with a safety profile similar to pravastatin alone and placebo.Conclusions When coadministered with pravastatin, ezetimibe provided significant incremental reductions in LDL-C and TG and was well tolerated with a safety profile similar to pravastatin alone. [ABSTRACT FROM PUBLISHER]

Published
2003
Full Text
View/download PDF

20. 831 FibroTest (Ft) Baseline Value Is An Independent Predictor of Early (EVR) and Sustained Virological Response (SVR) in Non-Responders Patients Re-Treated with Pegylated Interferon Alfa-2B (PEG-2B) and Ribavirin in EPIC3.

Author

Poynard, Thierry, Schiff, Eugene R., Terg, Ruben, Moreno-Otero, Ricardo, Flamm, Steven L., Schmidt, Warren N., Berg, Thomas, Goncales, Fernando L., Heathcote, Jenny, Diago, Moises, McGarrity, Thomas, Bedossa, Pierre, Zhou, Honghong, Mukhopadhyay, Pabak, Griffel, Louis H., Burroughs, Margaret, Brass, Clifford A., and Albrecht, Janice

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results